{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:54:00Z","timestamp":1754600040476},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ipilimumab (Ipi) plus nivolumab (Nivo) is the recommended first-line treatment for renal cell carcinoma (RCC). This report describes a case where pancreatic metastases disappeared after only two courses of Ipi\u2009+\u2009Nivo therapy. The primary tumor was cured by surgery, and a pathological Complete Response (pCR) was observed despite multiple serious immune-related Adverse Events (irAEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 54-year-old woman with RCC and pancreatic metastasis at stage IV, diagnosed with intermediate risk according to the International Metastatic RCC Database Consortium classification, underwent initiation of Ipi\u2009+\u2009Nivo therapy. On day 26, she developed hyperthyroidism accompanied by tachycardia, leading to the commencement of metoprolol tartrate treatment. Following the resolution of tachycardia, a second course of Ipi\u2009+\u2009Nivo therapy was administered on day 50. By day 70, the patient exhibited Grade 3 hepatic dysfunction, followed by the onset of hypothyroidism on day 75, necessitating treatment with steroids and levothyroxine. After positive treatment, a Grade 3 skin disorder emerged on day 87 while tapering steroids, prompting treatment with methylprednisolone (mPSL) pulse therapy. The skin disorder responded to steroids, allowing for tapering. However, on day 113, a recurrence of Grade 3 skin disorder occurred, necessitating another mPSL pulse. The patient responded well to treatment, exhibiting improvement in her condition. On day 131, she presented at the hospital with complaints of respiratory distress, prompting a Computed Tomography (CT) scan that revealed interstitial pneumonia. By day 272, subsequent CT imaging showed the disappearance of pancreatic metastasis and shrinkage of the primary tumor. On day 294, she underwent a laparoscopic left nephrectomy. Pathological analysis confirmed a pCR in the primary tumor, indicating successful eradication of RCC through surgical intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case report presents a scenario where multiple severe irAEs appeared in a patient, yet metastases disappeared after only two courses of Ipi\u2009+\u2009Nivo therapy. The patient was ultimately cured by surgery and achieved a pCR. This case highlights that despite the occurrence of severe irAEs during RCC treatment with Ipi\u2009+\u2009Nivo therapy, they can be managed appropriately to maximize the therapeutic effects of checkpoint inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-024-00348-8","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T08:02:01Z","timestamp":1717142521000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Ryo","family":"Takada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Maki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"348_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"348_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"348_CR3","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barth\u00e9l\u00e9my P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5:e001079.","journal-title":"ESMO Open"},{"key":"348_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jjco\/hyac009","volume":"52","author":"K Ueda","year":"2022","unstructured":"Ueda K, Suekane S, Kurose H, Ito N, Ogasawara N, Hiroshige T, et al. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol. 2022;52:479\u201385.","journal-title":"Jpn J Clin Oncol"},{"key":"348_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22:886\u201394.","journal-title":"Clin Cancer Res"},{"key":"348_CR6","first-page":"e2022132","volume":"93","author":"M Di Napoli","year":"2022","unstructured":"Di Napoli M, Pisano C, Setola SV, Perdon\u00e0 S, Feroce F, Pignata S. Nivolumab-ipilimumab in renal cell carcinoma metastatic to the bones: a case report. Acta Biomed. 2022;93:e2022132.","journal-title":"Acta Biomed"},{"key":"348_CR7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.21873\/invivo.11932","volume":"34","author":"S Shirotake","year":"2020","unstructured":"Shirotake S, Umezawa Y, Okabe T, Kaneko G, Kanao K, Nishimoto K, et al. Efficacy of nivolumab plus ipilimumab in a patient with renal cell carcinoma concomitant with cardiac metastasis: A case report. In Vivo. 2020;34:1475\u201380.","journal-title":"In Vivo"},{"key":"348_CR8","doi-asserted-by":"publisher","first-page":"980456","DOI":"10.3389\/fimmu.2022.980456","volume":"13","author":"Y Asano","year":"2022","unstructured":"Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, et al. Case report: complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors. Front Immunol. 2022;13:980456.","journal-title":"Front Immunol"},{"key":"348_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s13691-019-00389-z","volume":"9","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Sugiyama T, Otuka A, Miyake H. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. Int Cancer Conf J. 2020;9:32\u20135.","journal-title":"Int Cancer Conf J"},{"key":"348_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12470","volume":"279","author":"S Muenst","year":"2016","unstructured":"Muenst S, Laubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. J Intrern Med. 2016;279:541\u201362.","journal-title":"J Intrern Med"},{"key":"348_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","volume":"22","author":"PS Kim","year":"2010","unstructured":"Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22:223\u201330.","journal-title":"Curr Opin Immunol"},{"key":"348_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329\u201360.","journal-title":"Annu Rev Immunol"},{"key":"348_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","volume":"6","author":"DJ Martini","year":"2018","unstructured":"Martini DJ, Hamieh L, Nckay RR, Harshman LC, Brandao R, Norton CK, et al. Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-L1 therapy for immune-related adverse events. Cancer Immunol Res. 2018;6:402\u20138.","journal-title":"Cancer Immunol Res"},{"key":"348_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","volume":"16","author":"CM D\u0131\u0301az-Montero","year":"2020","unstructured":"D\u0131\u0301az-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16:721\u201335.","journal-title":"Nat Rev Nephrol"},{"key":"348_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119\u201332.","journal-title":"Lancet"},{"key":"348_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","volume":"9","author":"L Vuong","year":"2019","unstructured":"Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019;9:1349\u201357.","journal-title":"Cancer Discov"},{"key":"348_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","volume":"169","author":"S Chevrier","year":"2017","unstructured":"Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, et al. An immune atlas of clear cell renal cell carcinoma. Cell. 2017;169:736\u201349.e18.","journal-title":"Cell"},{"key":"348_CR18","doi-asserted-by":"publisher","first-page":"861328","DOI":"10.3389\/fimmu.2022.861328","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zheng XD, Zhu GQ, Li N, Zhou CW, Yang C, et al. Crosstalk between metabolism and immune activity reveals four subtype with therapeutic implications in clear cell renal cell carcinoma. Front Immunol. 2022;13:861328.","journal-title":"Front Immunol"},{"key":"348_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1753465816636557","volume":"10","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10:183\u201393.","journal-title":"Ther Adv Respir Dis"},{"key":"348_CR20","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607\u201316.","journal-title":"JAMA Oncol"},{"key":"348_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138.","journal-title":"JAMA Oncol"},{"key":"348_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11:45\u201354.","journal-title":"Lancet Respir Med"},{"key":"348_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.urolonc.2019.12.008","volume":"38","author":"H Ishihara","year":"2020","unstructured":"Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, et al. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urol Oncol. 2020;38:526\u201332.","journal-title":"Urol Oncol"},{"key":"348_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1080\/0284186X.2022.2104132","volume":"61","author":"E Kankkunen","year":"2022","unstructured":"Kankkunen E, Penttil\u00e4 P, Peltola K, Bono P. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. Acta Oncol. 2022;61:1240\u20137.","journal-title":"Acta Oncol"},{"key":"348_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3892\/etm.2023.12060","volume":"26","author":"Y Xu","year":"2023","unstructured":"Xu Y, Ma K, Zhang F, Ma M, Hong L, Wang J, et al. Association between baseline C-reactive protein level and survival outcome for cancer patients treated with immunotherapy: a meta-analysis. Exp Ther Med. 2023;26:361.","journal-title":"Exp Ther Med"},{"key":"348_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/cas.14710","volume":"112","author":"Y Saito","year":"2021","unstructured":"Saito Y, Sasaki S, Oikado K, Tominaga J, Sata M, Sakai F, et al. Radiographic features and poor prognostic factors of interstiti lung disease with nivolumab for non-small cell lung cancer. Cancer Sci. 2021;112:1495\u2013505.","journal-title":"Cancer Sci"},{"key":"348_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12890-021-01608-1","volume":"21","author":"M Eijima","year":"2021","unstructured":"Eijima M, Okamoto T, Suzuki T, Anzai T, Takahashi K, Miyazaki Y. Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis. BMC Pulm Med. 2021;21:243.","journal-title":"BMC Pulm Med"},{"key":"348_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fuziwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337\u201350.","journal-title":"J Bone Miner Metab"},{"key":"348_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EMJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"348_CR30","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00348-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00348-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T08:08:05Z","timestamp":1717142885000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00348-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00348-8","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted after obtaining verbal consent from the patient.The approval of the Ethical Review Committee of Fukuyama Medical Center was also secured (No. ERB2023018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}